Concepts (205)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Facial Injuries | 4 | 2015 | 25 | 0.980 |
Why?
|
| Graft Survival | 10 | 2024 | 935 | 0.970 |
Why?
|
| Pancreas Transplantation | 1 | 2024 | 104 | 0.880 |
Why?
|
| Comprehension | 1 | 2024 | 82 | 0.870 |
Why?
|
| Graft Rejection | 13 | 2024 | 1110 | 0.790 |
Why?
|
| Internet | 1 | 2024 | 331 | 0.760 |
Why?
|
| Facial Transplantation | 2 | 2012 | 17 | 0.750 |
Why?
|
| Patient Education as Topic | 1 | 2024 | 369 | 0.720 |
Why?
|
| Kidney Transplantation | 3 | 2024 | 863 | 0.710 |
Why?
|
| Tissue Donors | 6 | 2024 | 531 | 0.670 |
Why?
|
| Tissue and Organ Procurement | 4 | 2024 | 380 | 0.640 |
Why?
|
| Kidney Neoplasms | 1 | 2024 | 530 | 0.630 |
Why?
|
| Vascularized Composite Allotransplantation | 3 | 2022 | 17 | 0.550 |
Why?
|
| Skin Transplantation | 4 | 2020 | 192 | 0.510 |
Why?
|
| Batch Cell Culture Techniques | 1 | 2015 | 2 | 0.480 |
Why?
|
| Bioartificial Organs | 1 | 2015 | 3 | 0.480 |
Why?
|
| Esthetics | 3 | 2012 | 49 | 0.480 |
Why?
|
| Biomedical Engineering | 1 | 2015 | 21 | 0.480 |
Why?
|
| Organ Culture Techniques | 1 | 2015 | 129 | 0.470 |
Why?
|
| Facial Expression | 2 | 2012 | 56 | 0.470 |
Why?
|
| Composite Tissue Allografts | 3 | 2020 | 10 | 0.460 |
Why?
|
| Tissue Scaffolds | 1 | 2015 | 124 | 0.430 |
Why?
|
| Public Health | 2 | 2014 | 146 | 0.430 |
Why?
|
| Tissue Engineering | 1 | 2015 | 198 | 0.410 |
Why?
|
| Facial Dermatoses | 1 | 2012 | 14 | 0.390 |
Why?
|
| Facial Neoplasms | 1 | 2012 | 26 | 0.390 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2013 | 98 | 0.380 |
Why?
|
| Liver Transplantation | 3 | 2024 | 1186 | 0.380 |
Why?
|
| Body Image | 1 | 2012 | 81 | 0.370 |
Why?
|
| Social Stigma | 1 | 2012 | 76 | 0.360 |
Why?
|
| Hospitalists | 1 | 2013 | 141 | 0.360 |
Why?
|
| Interpersonal Relations | 1 | 2012 | 179 | 0.350 |
Why?
|
| Pattern Recognition, Visual | 1 | 2012 | 159 | 0.350 |
Why?
|
| Hospital Mortality | 1 | 2013 | 445 | 0.340 |
Why?
|
| Intensive Care Units | 1 | 2013 | 429 | 0.320 |
Why?
|
| Atherosclerosis | 2 | 2022 | 261 | 0.300 |
Why?
|
| Emotions | 1 | 2012 | 365 | 0.300 |
Why?
|
| Prognosis | 3 | 2024 | 3872 | 0.290 |
Why?
|
| Postoperative Complications | 4 | 2024 | 2454 | 0.290 |
Why?
|
| Immune Tolerance | 4 | 2022 | 360 | 0.290 |
Why?
|
| Tacrolimus | 2 | 2020 | 373 | 0.280 |
Why?
|
| Humans | 32 | 2024 | 92351 | 0.270 |
Why?
|
| Skin Neoplasms | 1 | 2012 | 605 | 0.270 |
Why?
|
| Transplantation Chimera | 2 | 2024 | 84 | 0.260 |
Why?
|
| Global Burden of Disease | 2 | 2023 | 12 | 0.260 |
Why?
|
| Living Donors | 2 | 2024 | 342 | 0.220 |
Why?
|
| Intestines | 2 | 2024 | 426 | 0.220 |
Why?
|
| Spike Glycoprotein, Coronavirus | 2 | 2021 | 45 | 0.220 |
Why?
|
| Intestinal Pseudo-Obstruction | 1 | 2023 | 7 | 0.210 |
Why?
|
| Waiting Lists | 1 | 2024 | 200 | 0.200 |
Why?
|
| Transplantation Tolerance | 1 | 2024 | 142 | 0.200 |
Why?
|
| Intestinal Obstruction | 1 | 2023 | 91 | 0.200 |
Why?
|
| Appendicitis | 1 | 2023 | 65 | 0.200 |
Why?
|
| Biliary Atresia | 1 | 2022 | 24 | 0.200 |
Why?
|
| Antibodies, Viral | 2 | 2021 | 301 | 0.200 |
Why?
|
| Abdominal Wall | 1 | 2022 | 30 | 0.190 |
Why?
|
| Vascular Diseases | 1 | 2022 | 120 | 0.180 |
Why?
|
| Surgical Procedures, Operative | 2 | 2014 | 210 | 0.180 |
Why?
|
| Immunodominant Epitopes | 1 | 2021 | 21 | 0.180 |
Why?
|
| Bacitracin | 1 | 2020 | 4 | 0.170 |
Why?
|
| Wound Healing | 3 | 2018 | 371 | 0.170 |
Why?
|
| Antibody Formation | 1 | 2021 | 171 | 0.170 |
Why?
|
| Immunosuppressive Agents | 2 | 2017 | 989 | 0.160 |
Why?
|
| B-Lymphocytes | 2 | 2021 | 753 | 0.160 |
Why?
|
| Transcriptome | 2 | 2021 | 701 | 0.150 |
Why?
|
| Thrombosis | 1 | 2022 | 313 | 0.150 |
Why?
|
| Host-Pathogen Interactions | 1 | 2021 | 239 | 0.150 |
Why?
|
| Patient Satisfaction | 2 | 2012 | 505 | 0.150 |
Why?
|
| Reproducibility of Results | 1 | 2024 | 2793 | 0.150 |
Why?
|
| Swine | 4 | 2024 | 607 | 0.140 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2024 | 925 | 0.140 |
Why?
|
| Perfusion | 3 | 2024 | 261 | 0.140 |
Why?
|
| Lung Transplantation | 1 | 2022 | 350 | 0.140 |
Why?
|
| Cyclosporine | 1 | 2018 | 241 | 0.130 |
Why?
|
| Tissue Preservation | 1 | 2017 | 15 | 0.130 |
Why?
|
| Developing Countries | 2 | 2014 | 81 | 0.130 |
Why?
|
| Pluripotent Stem Cells | 1 | 2016 | 36 | 0.130 |
Why?
|
| Regenerative Medicine | 1 | 2016 | 28 | 0.130 |
Why?
|
| Treatment Outcome | 5 | 2022 | 8730 | 0.130 |
Why?
|
| Immunity, Cellular | 1 | 2016 | 184 | 0.120 |
Why?
|
| Eye Injuries | 1 | 2015 | 15 | 0.120 |
Why?
|
| Swine, Miniature | 3 | 2024 | 53 | 0.120 |
Why?
|
| Male | 10 | 2024 | 43928 | 0.120 |
Why?
|
| Presumed Consent | 1 | 2014 | 2 | 0.120 |
Why?
|
| Ophthalmology | 1 | 2015 | 46 | 0.110 |
Why?
|
| Bioengineering | 1 | 2014 | 15 | 0.110 |
Why?
|
| Burns | 1 | 2017 | 145 | 0.110 |
Why?
|
| Animals | 9 | 2024 | 28059 | 0.110 |
Why?
|
| Cytokines | 3 | 2022 | 842 | 0.110 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2017 | 335 | 0.110 |
Why?
|
| Soft Tissue Injuries | 1 | 2013 | 16 | 0.110 |
Why?
|
| Transplantation, Heterologous | 1 | 2014 | 369 | 0.100 |
Why?
|
| Skin | 1 | 2017 | 595 | 0.100 |
Why?
|
| Dendritic Cells | 1 | 2017 | 478 | 0.100 |
Why?
|
| Checklist | 1 | 2013 | 68 | 0.100 |
Why?
|
| Lower Extremity | 1 | 2013 | 93 | 0.100 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2023 | 153 | 0.100 |
Why?
|
| Free Tissue Flaps | 1 | 2013 | 53 | 0.100 |
Why?
|
| Eyelid Neoplasms | 1 | 2012 | 7 | 0.100 |
Why?
|
| Dermoid Cyst | 1 | 2012 | 15 | 0.100 |
Why?
|
| Facial Muscles | 1 | 2012 | 24 | 0.100 |
Why?
|
| Facial Nerve Injuries | 1 | 2012 | 13 | 0.100 |
Why?
|
| Nerve Regeneration | 1 | 2012 | 37 | 0.100 |
Why?
|
| Trigeminal Nerve Injuries | 1 | 2012 | 16 | 0.100 |
Why?
|
| Sensory Receptor Cells | 1 | 2012 | 38 | 0.090 |
Why?
|
| Cicatrix | 1 | 2012 | 71 | 0.090 |
Why?
|
| Global Health | 2 | 2023 | 199 | 0.090 |
Why?
|
| United States | 1 | 2024 | 7367 | 0.090 |
Why?
|
| Neurofibromatoses | 1 | 2011 | 11 | 0.090 |
Why?
|
| Female | 9 | 2024 | 47901 | 0.090 |
Why?
|
| Microsurgery | 1 | 2012 | 97 | 0.090 |
Why?
|
| Retrospective Studies | 5 | 2024 | 9694 | 0.090 |
Why?
|
| Patient Safety | 1 | 2013 | 220 | 0.090 |
Why?
|
| Cross Reactions | 2 | 2021 | 110 | 0.090 |
Why?
|
| Motor Neurons | 1 | 2012 | 169 | 0.090 |
Why?
|
| Students | 1 | 2012 | 174 | 0.090 |
Why?
|
| Adult | 7 | 2024 | 27547 | 0.080 |
Why?
|
| Leukocytes | 2 | 2022 | 212 | 0.080 |
Why?
|
| Antibodies, Neutralizing | 2 | 2021 | 127 | 0.080 |
Why?
|
| Quality Improvement | 1 | 2014 | 474 | 0.080 |
Why?
|
| Surgical Flaps | 1 | 2012 | 254 | 0.080 |
Why?
|
| Cell Differentiation | 1 | 2016 | 1607 | 0.080 |
Why?
|
| Recovery of Function | 1 | 2011 | 318 | 0.080 |
Why?
|
| Administration, Topical | 2 | 2020 | 97 | 0.080 |
Why?
|
| Bandages | 2 | 2020 | 46 | 0.080 |
Why?
|
| Single-Cell Analysis | 2 | 2021 | 175 | 0.080 |
Why?
|
| Incidence | 2 | 2023 | 1661 | 0.080 |
Why?
|
| Sex Factors | 1 | 2012 | 1094 | 0.080 |
Why?
|
| Liver | 2 | 2022 | 1225 | 0.070 |
Why?
|
| Disease Models, Animal | 3 | 2020 | 2450 | 0.070 |
Why?
|
| Cross-Sectional Studies | 1 | 2012 | 1773 | 0.070 |
Why?
|
| Proof of Concept Study | 1 | 2024 | 51 | 0.060 |
Why?
|
| Surveys and Questionnaires | 1 | 2012 | 2730 | 0.050 |
Why?
|
| Quality of Life | 1 | 2012 | 1745 | 0.050 |
Why?
|
| End Stage Liver Disease | 1 | 2024 | 68 | 0.050 |
Why?
|
| Histocompatibility Testing | 1 | 2023 | 138 | 0.050 |
Why?
|
| Social Determinants of Health | 1 | 2024 | 103 | 0.050 |
Why?
|
| Young Adult | 2 | 2012 | 6629 | 0.050 |
Why?
|
| Portoenterostomy, Hepatic | 1 | 2022 | 5 | 0.050 |
Why?
|
| Adolescent | 2 | 2012 | 9495 | 0.050 |
Why?
|
| Bilirubin | 1 | 2022 | 134 | 0.050 |
Why?
|
| Transplantation Conditioning | 1 | 2024 | 380 | 0.050 |
Why?
|
| HLA Antigens | 1 | 2023 | 227 | 0.050 |
Why?
|
| Graft vs Host Disease | 1 | 2024 | 366 | 0.050 |
Why?
|
| Upper Extremity | 1 | 2022 | 62 | 0.050 |
Why?
|
| Epitope Mapping | 1 | 2021 | 17 | 0.050 |
Why?
|
| Neutralization Tests | 1 | 2021 | 71 | 0.040 |
Why?
|
| Transplant Recipients | 1 | 2022 | 152 | 0.040 |
Why?
|
| Organ Preservation | 1 | 2022 | 131 | 0.040 |
Why?
|
| Allografts | 1 | 2022 | 197 | 0.040 |
Why?
|
| Macaca fascicularis | 1 | 2020 | 110 | 0.040 |
Why?
|
| Gels | 1 | 2020 | 52 | 0.040 |
Why?
|
| Forelimb | 1 | 2020 | 20 | 0.040 |
Why?
|
| Antigens, Viral | 1 | 2021 | 133 | 0.040 |
Why?
|
| Immunity, Humoral | 1 | 2021 | 68 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2021 | 376 | 0.040 |
Why?
|
| Survival Rate | 1 | 2024 | 1926 | 0.040 |
Why?
|
| Epitopes | 1 | 2021 | 249 | 0.040 |
Why?
|
| Transplantation, Homologous | 1 | 2022 | 1015 | 0.040 |
Why?
|
| Immunologic Memory | 1 | 2021 | 177 | 0.040 |
Why?
|
| Middle Aged | 4 | 2024 | 27045 | 0.040 |
Why?
|
| Phosphoproteins | 1 | 2021 | 265 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 1 | 2021 | 248 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2023 | 437 | 0.040 |
Why?
|
| Heart | 1 | 2021 | 583 | 0.040 |
Why?
|
| Papio | 1 | 2018 | 85 | 0.040 |
Why?
|
| Computational Biology | 1 | 2021 | 568 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 499 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2024 | 3775 | 0.030 |
Why?
|
| Cryopreservation | 1 | 2017 | 72 | 0.030 |
Why?
|
| Random Allocation | 1 | 2017 | 328 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2017 | 229 | 0.030 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2017 | 81 | 0.030 |
Why?
|
| Inflammation | 1 | 2022 | 1024 | 0.030 |
Why?
|
| Antigen Presentation | 1 | 2017 | 219 | 0.030 |
Why?
|
| Trauma Severity Indices | 1 | 2015 | 46 | 0.030 |
Why?
|
| Histocompatibility | 1 | 2015 | 66 | 0.030 |
Why?
|
| Lung | 1 | 2022 | 1337 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2021 | 1480 | 0.030 |
Why?
|
| Major Histocompatibility Complex | 1 | 2015 | 85 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 2021 | 1241 | 0.030 |
Why?
|
| Interinstitutional Relations | 1 | 2014 | 30 | 0.030 |
Why?
|
| Health Priorities | 1 | 2014 | 24 | 0.030 |
Why?
|
| Health Facilities | 1 | 2014 | 41 | 0.030 |
Why?
|
| International Cooperation | 1 | 2014 | 127 | 0.030 |
Why?
|
| Risk Factors | 1 | 2024 | 5708 | 0.030 |
Why?
|
| Osteomyelitis | 1 | 2013 | 54 | 0.030 |
Why?
|
| Calcaneus | 1 | 2013 | 40 | 0.030 |
Why?
|
| Postoperative Care | 1 | 2014 | 238 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2014 | 156 | 0.030 |
Why?
|
| Patient Compliance | 1 | 2014 | 236 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2017 | 1804 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 2009 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2017 | 725 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2015 | 557 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2015 | 2903 | 0.020 |
Why?
|
| Comorbidity | 1 | 2013 | 986 | 0.020 |
Why?
|
| Heart Transplantation | 1 | 2015 | 774 | 0.020 |
Why?
|
| Aged | 2 | 2015 | 19952 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2013 | 760 | 0.020 |
Why?
|
| Time Factors | 1 | 2015 | 5431 | 0.020 |
Why?
|
| Infant | 1 | 2012 | 3206 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2015 | 2685 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2012 | 3806 | 0.010 |
Why?
|
| Child | 1 | 2012 | 7309 | 0.010 |
Why?
|